BACKGROUND: To facilitate prospective medical assessment of adults surviving pediatric malignancies and advance knowledge about long-term childhood cancer survivor health, St. Jude Children's Research Hospital (SJCRH) is establishing a lifetime cohort of survivors. METHODS: Eligibility criteria for inclusion in the St. Jude Lifetime Cohort (SJLIFE) study include: (1) diagnosis of childhood malignancy treated at SJCRH; (2) survival ≥ 10 years from diagnosis; and (3) current age ≥ 18 years. Three levels of participation are offered: (1) comprehensive evaluation on SJCRH campus; (2) limited home evaluation; or (3) completion of health surveys only. A systematic recruitment structure based upon blocks of 50 patients initially focused on leukemia and lymphoma survivors and patients eligible for pilot studies. RESULTS: As of January 1, 2010, 1,625 (42%) of 3,900 eligible ≥ 10-year survivors have been contacted. Among the first 1,000 potentially eligible survivors selected for recruitment, 971 were subsequently confirmed to fulfill eligibility criteria. To date, 898/971 (92.5%) have been successfully contacted of whom 825 (91.8%) have agreed to participate. Among participants, 88.6% agreed to comprehensive medical evaluation, 0.4% limited local evaluation, and 11.0% survey only. Anticipated minimum overall participation rate for medical evaluation is 75.3% (731/971). Comparison of those contacted who agreed versus declined to participate revealed a greater proportion of males who declined participation (P = 0.001). CONCLUSIONS: Early results of the SJLIFE study support its feasibility to recruit aging childhood cancer survivors to research investigations evaluating late health outcomes by medical assessments.
BACKGROUND: To facilitate prospective medical assessment of adults surviving pediatric malignancies and advance knowledge about long-term childhood cancer survivor health, St. Jude Children's Research Hospital (SJCRH) is establishing a lifetime cohort of survivors. METHODS: Eligibility criteria for inclusion in the St. Jude Lifetime Cohort (SJLIFE) study include: (1) diagnosis of childhood malignancy treated at SJCRH; (2) survival ≥ 10 years from diagnosis; and (3) current age ≥ 18 years. Three levels of participation are offered: (1) comprehensive evaluation on SJCRH campus; (2) limited home evaluation; or (3) completion of health surveys only. A systematic recruitment structure based upon blocks of 50 patients initially focused on leukemia and lymphoma survivors and patients eligible for pilot studies. RESULTS: As of January 1, 2010, 1,625 (42%) of 3,900 eligible ≥ 10-year survivors have been contacted. Among the first 1,000 potentially eligible survivors selected for recruitment, 971 were subsequently confirmed to fulfill eligibility criteria. To date, 898/971 (92.5%) have been successfully contacted of whom 825 (91.8%) have agreed to participate. Among participants, 88.6% agreed to comprehensive medical evaluation, 0.4% limited local evaluation, and 11.0% survey only. Anticipated minimum overall participation rate for medical evaluation is 75.3% (731/971). Comparison of those contacted who agreed versus declined to participate revealed a greater proportion of males who declined participation (P = 0.001). CONCLUSIONS: Early results of the SJLIFE study support its feasibility to recruit aging childhood cancer survivors to research investigations evaluating late health outcomes by medical assessments.
Authors: Ching-Hon Pui; Deqing Pei; John T Sandlund; Dario Campana; Raul C Ribeiro; Bassem I Razzouk; Jeffrey E Rubnitz; Scott C Howard; Nobuko Hijiya; Sima Jeha; Cheng Cheng; James R Downing; William E Evans; Mary V Relling; Melissa Hudson Journal: J Clin Oncol Date: 2005-11-01 Impact factor: 44.544
Authors: Steven E Lipshultz; Stuart R Lipsitz; Stephen E Sallan; Virginia M Dalton; Suzanne M Mone; Richard D Gelber; Steven D Colan Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: Wendy Landier; Smita Bhatia; Debra A Eshelman; Katherine J Forte; Teresa Sweeney; Allison L Hester; Joan Darling; F Daniel Armstrong; Julie Blatt; Louis S Constine; Carolyn R Freeman; Debra L Friedman; Daniel M Green; Neyssa Marina; Anna T Meadows; Joseph P Neglia; Kevin C Oeffinger; Leslie L Robison; Kathleen S Ruccione; Charles A Sklar; Melissa M Hudson Journal: J Clin Oncol Date: 2004-12-02 Impact factor: 44.544
Authors: M L Garrè; S Gandus; B Cesana; R Haupt; B De Bernardi; A Comelli; A Ferrando; G Stella; M L Vitali; P Picco Journal: Am J Pediatr Hematol Oncol Date: 1994-05
Authors: Daniel C Bowers; D Elizabeth McNeil; Yan Liu; Yutaka Yasui; Marilyn Stovall; James G Gurney; Melissa M Hudson; Sarah S Donaldson; Roger J Packer; Pauline A Mitby; Catherine E Kasper; Leslie L Robison; Kevin C Oeffinger Journal: J Clin Oncol Date: 2005-09-20 Impact factor: 50.717
Authors: Lillian R Meacham; James G Gurney; Ann C Mertens; Kirsten K Ness; Charles A Sklar; Leslie L Robison; Kevin C Oeffinger Journal: Cancer Date: 2005-04-15 Impact factor: 6.921
Authors: Mylène Bassal; Ann C Mertens; Leslie Taylor; Joseph P Neglia; Brian S Greffe; Sue Hammond; Cécile M Ronckers; Debra L Friedman; Marilyn Stovall; Yutaka Y Yasui; Leslie L Robison; Anna T Meadows; Nina S Kadan-Lottick Journal: J Clin Oncol Date: 2006-01-20 Impact factor: 50.717
Authors: Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison Journal: N Engl J Med Date: 2006-10-12 Impact factor: 176.079
Authors: Joseph P Neglia; Leslie L Robison; Marilyn Stovall; Yan Liu; Roger J Packer; Sue Hammond; Yutaka Yasui; Catherine E Kasper; Ann C Mertens; Sarah S Donaldson; Anna T Meadows; Peter D Inskip Journal: J Natl Cancer Inst Date: 2006-11-01 Impact factor: 11.816
Authors: Daniel M Green; Liang Zhu; Mingjuan Wang; Kirsten K Ness; Matthew J Krasin; Nickhill H Bhakta; M Beth McCarville; Saumini Srinivasan; Dennis C Stokes; DeoKumar Srivastava; Rohit Ojha; Kyla Shelton; Ching-Hon Pui; Gregory T Armstrong; Daniel A Mulrooney; Monika Metzger; Sheri L Spunt; Fariba Navid; Andrew M Davidoff; Bhaskar N Rao; Leslie L Robison; Melissa M Hudson Journal: Ann Am Thorac Soc Date: 2016-09
Authors: Robyn E Karlage; Carmen L Wilson; Nan Zhang; Sue Kaste; Daniel M Green; Gregory T Armstrong; Leslie L Robison; Wassim Chemaitilly; Deo Kumar Srivastava; Melissa M Hudson; Kirsten K Ness Journal: Cancer Date: 2015-02-27 Impact factor: 6.860
Authors: Susan Ogg; James L Klosky; Wassim Chemaitilly; Deo Kumar Srivastava; Mingjuan Wang; Ginger Carney; Rohit Ojha; Leslie L Robison; Cheryl L Cox; Melissa M Hudson Journal: J Cancer Surviv Date: 2020-04-14 Impact factor: 4.442
Authors: J G Gurney; S C Kaste; W Liu; D K Srivastava; W Chemaitilly; K K Ness; J Q Lanctot; R P Ojha; K A Nottage; C L Wilson; Z Li; L L Robison; M M Hudson Journal: Pediatr Blood Cancer Date: 2014-02-28 Impact factor: 3.167
Authors: Israel Fernandez-Pineda; Andrew M Davidoff; Lu Lu; Bhaskar N Rao; Carmen L Wilson; D Kumar Srivastava; James L Klosky; Monica L Metzger; Matthew J Krasin; Kirsten K Ness; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson; Charles A Sklar; Daniel M Green; Wassim Chemaitilly Journal: Pediatr Blood Cancer Date: 2018-05-11 Impact factor: 3.167
Authors: Tara M Brinkman; Wilburn E Reddick; Joshua Luxton; John O Glass; Noah D Sabin; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: Neuro Oncol Date: 2012-09 Impact factor: 12.300
Authors: Deborah B Crom; Kirsten K Ness; Larry R Martinez; Michelle R Hebl; Leslie L Robison; Melissa M Hudson; Tara M Brinkman Journal: J Cancer Surviv Date: 2018-03-17 Impact factor: 4.442
Authors: Laura van Iersel; Zhenghong Li; Deo Kumar Srivastava; Tara M Brinkman; Kari L Bjornard; Carmen L Wilson; Daniel M Green; Thomas E Merchant; Ching-Hon Pui; Rebecca M Howell; Susan A Smith; Gregory T Armstrong; Melissa M Hudson; Leslie L Robison; Kirsten K Ness; Amar Gajjar; Kevin R Krull; Charles A Sklar; Hanneke M van Santen; Wassim Chemaitilly Journal: J Clin Endocrinol Metab Date: 2019-12-01 Impact factor: 5.958
Authors: Hsiu-Ju Yen; Hesham M Eissa; Neel S Bhatt; Sujuan Huang; Matthew J Ehrhardt; Nickhill Bhakta; Kirsten K Ness; Kevin R Krull; D Kumar Srivastava; Leslie L Robison; Melissa M Hudson; I-Chan Huang Journal: Blood Date: 2020-05-21 Impact factor: 22.113